BRIEF published on 07/24/2024 at 12:52, 2 years 1 month ago Duke Capital Achieves Record Cashflows in FY'24 Financial Performance Dividend Yield DUKE Capital Record Cashflows FY’24
BRIEF published on 07/24/2024 at 12:52, 2 years 1 month ago Duke Capital réalise des flux de trésorerie records au cours de l'exercice 24 Performance Financière DUC Capitale Enregistrer Les Flux De Trésorerie AF'24 Rendement En Dividendes
BRIEF published on 07/24/2024 at 12:49, 2 years 1 month ago Manz AG Successfully Completes Sale of Hungarian Subsidiary Manz AG Liquidity Improvement Production Optimization Subsidiary Sale Harro Höfliger
BRIEF published on 07/24/2024 at 12:49, 2 years 1 month ago Manz AG finalise avec succès la vente de sa filiale hongroise Manz AG Amélioration De La Liquidité Optimisation De La Production Vente De Filiale Harro Höfliger
BRIEF published on 07/24/2024 at 12:35, 2 years 1 month ago Immunic, Inc. Strengthens Its Board with Appointment of Simona Skerjanec Drug Development Board Appointment Immunic Simona Skerjanec Pharmaceutical Experience
BRIEF published on 07/24/2024 at 12:35, 2 years 1 month ago Immunic, Inc. renforce son conseil d'administration avec la nomination de Simona Skerjanec Nomination Au Conseil D'administration Immunitaire Développement De Médicaments Simona Skerjanec Expérience Pharmaceutique
BRIEF published on 07/24/2024 at 12:35, 2 years 1 month ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
BRIEF published on 07/24/2024 at 12:35, 2 years 1 month ago Palvella Therapeutics et Pieris Pharmaceuticals annoncent un accord de fusion définitif Financement Nasdaq Biopharmaceutique Fusionnement QTORIN™
BRIEF published on 07/24/2024 at 12:35, 2 years 1 month ago NanoViricides Highlights NV-387's Potential Against COVID-19 COVID-19 NanoViricides NV-387 Clinical Trials Antiviral
BRIEF published on 07/24/2024 at 12:35, 2 years 1 month ago Les nanoviricides mettent en évidence le potentiel du NV-387 contre le COVID-19 NanoViricides NV-387 Essais Cliniques COVID 19 Antiviral
Published on 09/12/2026 at 02:35, 1 day 3 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 7 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 9 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 13 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 12 hours 35 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 22 hours 55 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 8 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 8 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 10 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 1 day 23 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 23 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 10 hours ago Availability of the 2026 Interim Financial Report
